Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Pediatrix Medical Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
Pediatrix Medical Group şirketinin toplam hissedar öz sermayesi $706.5M ve toplam borcu $630.4M olup, bu da borç-öz sermaye oranını 89.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.0B ve $1.3B dir. Pediatrix Medical Group 'in FAVÖK'ü $152.4M faiz karşılama oranı 4.1 dur. Şirketin $133.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
89.2%
Borç/özkaynak oranı
US$630.37m
Borç
| Faiz karşılama oranı | 4.1x |
| Nakit | US$133.20m |
| Eşitlik | US$706.46m |
| Toplam yükümlülükler | US$1.29b |
| Toplam varlıklar | US$2.00b |
Son finansal sağlık güncellemeleri
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Recent updates
We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?
Nov 17These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well
Oct 23Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Oct 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: MD 'nin kısa vadeli varlıkları ( $429.2M ) kısa vadeli yükümlülüklerini ( $310.2M ) aşıyor.
Uzun Vadeli Yükümlülükler: MD 'un kısa vadeli varlıkları ( $429.2M ) uzun vadeli yükümlülüklerini ( $978.7M ) karşılamamaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: MD 'nin net borç/öz sermaye oranı ( 70.4% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: MD şirketinin borç/öz sermaye oranı son 5 yılda 76.3% seviyesinden 89.2% seviyesine yükseldi.
Borç Kapsamı: MD 'nin borcu işletme nakit akışı ( 20.8% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: MD 'in borcuna ilişkin faiz ödemeleri EBIT ( 4.1 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.